Resistant Hypertension: Diagnosis, Evaluation, and Treatment

Hypertension - Tập 51 Số 6 - Trang 1403-1419 - 2008
David A. Calhoun, Daniel Jones, Stephen C. Textor1, David C. Goff, Timothy P. Murphy, Robert D. Toto2, Anthony J. White, William C. Cushman, William B. White, Domenic A. Sica, Keith C. Ferdinand, Thomas D. Giles, Bonita Falkner, Robert M. Carey
1Nephrology and Hypertension
2Internal Medicine

Tóm tắt

Resistant hypertension is a common clinical problem faced by both primary care clinicians and specialists. While the exact prevalence of resistant hypertension is unknown, clinical trials suggest that it is not rare, involving perhaps 20% to 30% of study participants. As older age and obesity are 2 of the strongest risk factors for uncontrolled hypertension, the incidence of resistant hypertension will likely increase as the population becomes more elderly and heavier. The prognosis of resistant hypertension is unknown, but cardiovascular risk is undoubtedly increased as patients often have a history of long-standing, severe hypertension complicated by multiple other cardiovascular risk factors such as obesity, sleep apnea, diabetes, and chronic kidney disease. The diagnosis of resistant hypertension requires use of good blood pressure technique to confirm persistently elevated blood pressure levels. Pseudoresistance, including lack of blood pressure control secondary to poor medication adherence or white coat hypertension, must be excluded. Resistant hypertension is almost always multifactorial in etiology. Successful treatment requires identification and reversal of lifestyle factors contributing to treatment resistance; diagnosis and appropriate treatment of secondary causes of hypertension; and use of effective multidrug regimens. As a subgroup, patients with resistant hypertension have not been widely studied. Observational assessments have allowed for identification of demographic and lifestyle characteristics associated with resistant hypertension, and the role of secondary causes of hypertension in promoting treatment resistance is well documented; however, identification of broader mechanisms of treatment resistance is lacking. In particular, attempts to elucidate potential genetic causes of resistant hypertension have been limited. Recommendations for the pharmacological treatment of resistant hypertension remain largely empiric due to the lack of systematic assessments of 3 or 4 drug combinations. Studies of resistant hypertension are limited by the high cardiovascular risk of patients within this subgroup, which generally precludes safe withdrawal of medications; the presence of multiple disease processes (eg, sleep apnea, diabetes, chronic kidney disease, atherosclerotic disease) and their associated medical therapies, which confound interpretation of study results; and the difficulty in enrolling large numbers of study participants. Expanding our understanding of the causes of resistant hypertension and thereby potentially allowing for more effective prevention and/or treatment will be essential to improve the long-term clinical management of this disorder.

Từ khóa


Tài liệu tham khảo

10.1001/jama.290.2.199

10.1161/hyp.36.4.594

10.1161/01.hyp.0000164577.81087.70

10.1001/jama.288.23.2981

10.1111/j.1524-6175.2002.02045.x

Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115–129 mm Hg. JAMA. 1967; 202: 1038–1034.

10.1161/01.hyp.0000035855.44620.da

10.1186/1471–2350–6–4

10.1152/japplphysiol.00322.2003

10.1161/01.hyp.0000151361.31736.96

10.1161/01.cir.0000154900.76284.f6

10.1097/00149831-200506000-00010

Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999; 160: 41–46.

10.1097/01.hjh.0000186832.41125.8a

10.1097/01.hjh.0000187261.40190.2e

10.1016/j.amjhyper.2004.11.021

10.1016/S0895-7061(01)02193-8

10.1161/01.hyp.0000172757.96281.bf

10.1016/j.amjhyper.2005.05.014

10.1097/00126097-200310000-00001

10.1161/hyp.31.2.712

10.1016/j.amjhyper.2004.05.017

10.1016/j.amjhyper.2005.01.002

10.1161/01.hyp.0000052314.95497.78

He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. The Cochrane Database of Systemic Reviews. 2004; (3): CD004937.

Luft FC, Weinberger MH. Review of salt restriction and the response to antihypertensive drugs: satellite symposium on calcium antagonists. Hypertension. 1988; 11 (suppl I): I-229–I-232.

10.1001/jama.1988.03720170037030

10.1016/j.amjhyper.2004.08.031

10.1097/01.hjh.0000163141.82212.5f

10.1111/j.0954-6820.1980.tb09716.x

10.1161/hyp.33.2.653

10.1161/01.hyp.0000035856.77718.da

10.1161/01.hyp.0000177437.07240.70

10.7326/0003-4819-121-4-199408150-00011

10.7326/0003-4819-107-5-628

10.1161/hyp.36.3.461

10.1016/S0002-9149(02)02661-9

10.1161/01.hyp.0000014323.99765.16

10.1161/01.hyp.0000158267.66763.63

10.7326/0003-4819-136-1-200201010-00010

10.1016/S0895-7061(01)02172-0

10.1016/S0889-8529(18)30102-6

10.1093/ndt/14.1.218

10.1056/NEJM199304293281704

10.1097/00004872-199405000-00015

10.1210/jc.2003-032179

10.1001/jama.283.14.1829

10.1056/NEJM200005113421901

10.1097/00004872-200112000-00022

10.1097/00004872-200018060-00004

10.1093/sleep/24.6.721

10.1172/JCI118235

10.1161/01.hyp.0000174243.39897.6c

10.1385/JMN:21:1:57

10.1007/s11325-005-0024-z

10.1161/01.hyp.0000079505.25750.11

Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Soto J, Gómez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000; 85: 1863–1867.

10.1111/j.1440-1681.1994.tb02519.x

10.1161/01.hyp.0000040261.30455.b6

10.1016/S0272-6386(01)80117-7

10.1097/00004872-200411000-00026

10.1161/01.hyp.0000154361.47683.d3

10.1054/plef.2002.0414

10.1073/pnas.2336140100

10.1378/chest.125.1.112

10.1291/hypres.27.193

10.1001/archinte.1987.00370070103015

10.1111/j.1524-6175.2002.01452.x

10.1097/01.hjh.0000185714.60788.52

10.1097/00004872-200409000-00012

10.1161/hyp.36.5.901

10.1007/BF02067379

10.1210/jc.2004-1398

Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clinic Proc. 1981; 56: 354–360.

10.1016/S0140-6736(05)67139-5

10.1053/snep.2002.28670

10.1016/S1521-690X(03)00053-8

McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001; 86: 713–718.

10.1007/s11906-005-0013-4

10.1007/s11102-005-1172-7

10.1016/S0735-1097(03)00493-5

10.1210/jc.2002-021558

10.1016/S0272-6386(96)90380-7

10.1056/NEJM199403313301301

10.1001/archinte.161.9.1207

10.1080/08037050510008959

10.1097/00004872-200306000-00016

10.1016/S0002-8703(98)70138-3

10.1056/NEJM200004063421403

10.1093/ndt/18.2.298

10.1056/NEJM200102083440607

10.1007/s00330-005-2826-6

10.1148/radiology.207.2.9577501

10.1001/archinte.161.22.2661

10.1001/jama.289.19.2560

10.1097/00126097-200402000-00006

10.1097/00126097-200402000-00007

10.1016/j.amjhyper.2005.10.017

10.1373/clinchem.2004.041780

10.1210/jc.2002-021251

10.1097/00005650-199412000-00004

10.1111/j.1524-6175.2006.04872.x

10.1007/s10557-005-6127-8

10.1161/01.hyp.0000165680.59733.d4

10.1161/01.hyp.0000094221.86888.ae

10.1161/01.hyp.0000171474.84969.7a

10.7326/0003-4819-135-12-200112180-00005

10.1161/01.hyp.17.6.798

10.1056/NEJM199511303332204

10.7326/0003-4819-136-7-200204020-00006

10.1056/NEJM199704173361601

10.1161/01.cir.0000042706.47107.7a

10.1183/09031936.03.00035402

10.1016/S0140-6736(02)07445-7

10.7326/0003-4819-134-11-200106050-00007

10.1136/thx.2003.015875

10.1053/ejvs.2001.1559

10.1161/01.hyp.0000037218.09310.81

10.7326/0003-4819-145-12-200612190-00143

10.1161/01.hyp.0000016176.16042.2f

10.1016/S0895-7061(02)03260-0

10.1161/01.hyp.0000203309.07140.d3

10.1001/jama.1991.03460240051027

10.1161/circ.82.5.2225366

10.1161/01.hyp.0000203147.75714.ba

Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens. 1995; 9: 791–796.

10.1038/clpt.1990.210

10.1016/S0895-7061(01)02097-0

10.1038/sj.jhh.1000688

10.1038/sj.jhh.1001511

10.1161/hyp.28.1.109

10.1097/00005344-200006000-00017

10.1097/01.hjh.0000163159.22116.ab

10.1016/S0895-7061(03)01032-X

10.1016/S0895-7061(01)02342-1

10.1161/01.hyp.0000179582.42830.1d

10.1001/jama.282.6.539

10.1161/01.hyp.0000152079.04553.2c

10.1016/S0895-7061(03)01030-6

Thông tin
Thông tin xuất bản

Hypertension

Tập 51 Số 6

1403-1419

Thông tin tác giả